Brazil firms say regulations could hinder biotech sugar cane advances

03/4/2008 | Reuters

Brazil-based biotech companies on Tuesday said strict regulation in the country could keep biotech sugar cane off the market for as long as seven years. Alellyx Applied Genomics plans to unveil its sugar cane variety for commercial use in 2013 or 2014 "if there are no major regulation setbacks," the company's scientific director said.

View Full Article in:


Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Sr. Regulatory Specialist, Biotech Center of Expertise
BASF, The Chemical Co.
San Diego, CA
Food Lawyer
Wayzata, MN
Director of Clinical Research
Regenesis Biomedical, Inc.
Scottsdale, AZ
Meridian Health Plan
Detroit, MI
Assistant Vice President - Dental Director
Bridgewater, NJ